Company Overview

Incorporated in 1987, Bal Pharma Ltd (BPL) is a member of the Mcro Laboratories Group and operates as a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. The company initially commenced operations by taking over a pharmaceutical manufacturing unit in Bangalore in March 1990 through the Karnataka State Finance Corporation.

The company focuses on therapeutic areas including Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and Dermatology. Bal Pharma is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes. The company manufactures and markets pharmaceutical formulations including paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, among others.

Business Operations and Expansion

In 2016-17, Bal Pharma commenced construction of a fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. The company further expanded in 2017-18 by acquiring 100% stake in Golden Drugs Private Ltd, an Udaipur-based manufacturer of bulk drugs and intermediates for Rs 14 Crores.

The company earmarked Rs 36 Crores for setting up a bulk drug manufacturing unit at Yadgir District, Karnataka in 2022-23. In 2023, it launched Sitagliptin (a DPP-4 Inhibitor) in plain form and as a combination with Metformin under the brand names SITABEND & SITABEND-M. Bal Pharma has grown from humble beginnings to become a USD 30 Million company today.

Stock Performance and Market Presence

Bal Pharma Ltd has a market capitalisation of Rs 149-159 crore as of July 2025. The stock's 52-week high stands at Rs 157.90-157.98 while the 52-week low is Rs 76.30-78.06. Key financial ratios include a P/E ratio of 22.0-22.75, book value of Rs 48.6, dividend yield of 1.21%, ROCE of 10.1%, and ROE of 9.84%.

Promoter holding in Bal Pharma Ltd stands at 50.86% as of June 2025, remaining stable from September 2024. The company is listed on both BSE (Code: 524824) and NSE (Symbol: BALPHARMA) with ISIN code INE083D01012.

Financial Performance

On a consolidated basis, Bal Pharma Ltd reported a profit of Rs 5.42 crore on total income of Rs 82.96 crore for Q1 2025. For the financial year ended 2024, the company posted a profit of Rs 7.45 crore on total income of Rs 339.22 crore.

Recent quarterly performance shows mixed results. For Q1 2024, net profit rose 225% to Rs 0.26 crore compared to Rs 0.08 crore in Q1 2023, while sales increased 5.64% to Rs 74.36 crore from Rs 70.39 crore. However, in Q3 2024, net profit declined 7.94% to Rs 1.16 crore and sales dropped 10.55% to Rs 72.89 crore compared to the previous year.

Key Financial Metrics

- Q1 FY2025 Performance: Net Profit of Rs 5.42 crore, Total Income of Rs 82.96 crore

- FY2024 Performance: Net Profit of Rs 7.45 crore, Total Income of Rs 339.22 crore

- Q1 FY2024 vs Q1 FY2023: Net Profit increased 225% to Rs 0.26 crore, Sales increased 5.64% to Rs 74.36 crore

- Q3 FY2024 vs Previous Year: Net Profit declined 7.94% to Rs 1.16 crore, Sales dropped 10.55% to Rs 72.89 crore

- Trailing 12 Months: Revenue of Rs 315.83 crores

- Annual Revenue Growth: 12%

- Pre-tax Margin: 3%

- Return on Equity (ROE): 10% (recent), 8.51% (last 3 years average)

- Debt to Equity Ratio: 52%

Strategic Developments

The company has scheduled a board meeting on August 11, 2025, to consider unaudited financial results for Q1 2025, convene the 38th Annual General Meeting, fix book closure dates, discuss Employee Stock Option Plan-2025, and approve the merger of Lifezen Healthcare Pvt Ltd (subsidiary) with Bal Pharma Ltd.

The company exports Finished Dosage Forms (FDF) to Semi-Regulated and Non-Regulated markets and is now foraying into regulated markets. Bal Pharma is also positioning itself as a strong contender for World Tender Business.

Market Assessment

While the company shows good annual revenue growth of 12% and ROE of 10%, analysts note that the pre-tax margin of 3% needs improvement and the debt to equity ratio of 52% is relatively high. The company faces challenges including a low interest coverage ratio and relatively low return on equity of 8.51% over the last 3 years.

The pharmaceutical sector positioning and focus on diabetes care through Gliclazide production provides the company with a stable therapeutic niche, while ongoing capacity expansion and regulatory market entry initiatives indicate growth potential for the future.